Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
Trial details
- Registry ID
- NCT06206278
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as BBP-831; BGJ398
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaNCT06206278 | LianBio LLC | Phase 2 | Terminated | 2024-05-31Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |